Its introduction in 2001 completely replaced interferon-alpha (IFN-α) as standard CML treatment, providing high remission rates, fewer side effects and significantly improved patient survival (8–10). This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.